Stephen A. Tullman, Director at Aclaris Therapeutics, Inc. (ACRS), bought 6,600 shares at $15.00 ($99K) on 2018-08-23, disclosed to the SEC on 2018-08-27.
Open-market purchase of $99k ACRS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| ACRS | BUY | 2018-04-09 | $442K | — | Filing → |